sEphB4-HSA for Kaposi Sarcoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.
Who Is on the Research Team?
Ida Wong-Sefidan
Principal Investigator
AIDS Malignancy Consortium
Are You a Good Fit for This Trial?
This trial is for individuals with Kaposi Sarcoma, which may include those who haven't been treated before or those who didn't respond to or couldn't tolerate previous treatments. HIV-positive participants are welcome if they're on stable antiretroviral therapy. Participants need a life expectancy over 3 months and must have skin lesions suitable for biopsy. They should not be pregnant and must agree to use effective birth control methods.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses may receive treatment on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion. Patients with partial response or better are followed up every 3 months for up to 1 year.
What Are the Treatments Tested in This Trial?
Interventions
- Recombinant EphB4-HSA Fusion Protein
Find a Clinic Near You
Who Is Running the Clinical Trial?
AIDS Malignancy Consortium
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Vasgene Therapeutics, Inc
Industry Sponsor
The Emmes Company, LLC
Industry Sponsor
Peter Ronco
The Emmes Company, LLC
Chief Executive Officer since 2023
BSc from Nottingham University
Dr. Joe Sliman
The Emmes Company, LLC
Chief Medical Officer since 2020
MD from Uniformed Services University of the Health Sciences, MPH from Johns Hopkins University, BSc in Molecular and Cell Biology from Pennsylvania State University
University of Arkansas
Collaborator